Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats

Journal of Hypertension

Volumn 28, Issue 5, 2010, Pages 1007-1019

  Toblli, Jorge E ^a   Cao, Gabriel ^a   Rivas, Carlos ^a   Munoz, Marina ^b   Giani, Jorge ^b   Dominici, Fernando ^b   Angerosa, Margarita ^a  

^a Hospital Alemá N   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aorta; Beta blockers; Heart; Metabolic syndrome; Zucker diabetic fatty rat

Indexed keywords

ATENOLOL; CATALASE; CHOLESTEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INSULIN; MALONALDEHYDE; NEBIVOLOL; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MUSCLE RELAXATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; VASODILATATION; ZUCKER DIABETIC FATTY RAT;

EID: 77951287071     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328337598c     Document Type: Article

References (44)

1. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004; 33:351-375. (Pubitemid 38680634)
2. Reaven G. The metabolic syndrome or the insulin resistant syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004; 33:283-303. (Pubitemid 38680631)
3. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996-1002. (Pubitemid 32295654)
4. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005; 28:2436-2440. (Pubitemid 41384290)
5. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all cause in United States adults. Circulation 2004; 110:1245-1250. (Pubitemid 39202340)
6. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serumuric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-480. (Pubitemid 37237341)
7. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia: evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 1992; 35:873-879.
8. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41:1072-1079. (Pubitemid 36548605)
9. Benthem L, Kuipers F, Steffens AB, Scheurink AJW. Excessive portal venous supply of long-chain free fatty acids to the liver, leading to hypothalamus-pituitary-adrenalaxis and sympathetic activation as a key to the development of syndrome X. Ann N Y Acad Sci 1999; 892:308-311.
10. Bray GA. The Zucker-fatty rat: a review. Fed Proc 1977; 36:148-153.
11. Kava R, Greenwood MR, Johnson PR. Zucker (fa/fa) rats. ILAR News 1990; 32:4-8.
12. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989; 13:896-901.
13. Toblli JE, Cao G, Casas G, Mazza ON. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. Am J Hypertens 2006; 19:1226-1232. (Pubitemid 44856250)
14. Toblli J, Stella I, Né stor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. Am J Hypertens 2004; 17:516-522. (Pubitemid 38726167)
15. Carusio N, Wangensteen R, Filippelli A, Andriantsitohaina R. Oral administration of polyphenolic compounds from cognac decreases ADP-induced platelet aggregation and reduces chronotropic effect of isoprenaline in rats. Physiol Res 2008; 57:517-524.
16. Chance B, Maehly A. Assay of catalase and peroxidase. In: Colowick SP, Kaplan NO, editors. Methods in enzymology, Vol.2. New York: Academic Press; 1955. pp. 764-768.
17. Paoletti F, Aldinucci D, Mocall A, Caparrini A. A sensitive spectrophotometric method for the determination of superoxide dismutase activity in tissue extracts. Anal Biochem 1986; 154:536-541. (Pubitemid 16075292)
18. Niehaus W, Samuelson B. Formation of malondialdehyde from phospholipids arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6:126-130.
19. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin-phenol reagent. J Biol Chem 1954; 193:265-275.
20. Toblli JE, DeRosa G, Rivas C, Cao G, Piorno P, Pagano P, Forcada P. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. J Hypertens 2003; 21:611-620. (Pubitemid 36418974)
21. Kovanecz I, Nolazco G, Ferrini MG, Toblli JE, Heydarkhan S, Vernet D, et al. Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction. BJU Int 2009; 103:1396-1404.
22. Giani JF, Gironacci MM, Muñoz MC, Peña C, Turyn D, Dominici FP. Angiotensin-(1-7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ Physiol 2007; 293:H1154-H1163. (Pubitemid 47254217)
23. Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Irbersartan restores the in vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 2006; 24:1607-1617. (Pubitemid 44162463)
24. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8:127-134. (Pubitemid 36701937)
25. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67:1097-1107. (Pubitemid 46871021)
26. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 1994; 8:65-73.
27. Picano E. Diabetic cardiomyopathy. The importance of being earliest. J Am Coll Cardiol 2003; 42:454-457. (Pubitemid 36951710)
28. El-Omar MM, Yang ZK, Phillips AO, Shah AM. Cardiac dysfunction in the Goto-Kakizaki rat. A model of type II diabetes mellitus. Basic Res Cardiol 2004; 99:133-141. (Pubitemid 38325025)
29. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23:599-622.
30. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18:655-673. (Pubitemid 30406736)
31. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin F2a. Hypertension 1999; 33:424-428.
32. Chen YF, Cowley AW, Zou AP. Increased H2O2 counters the vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol 2003; 285:R827-R833.
33. Charloux C, Paul M, Loisance D, Astier A. Inhibition of hydroxyl radical produced by lactobionate, adenine, and tempol. Free Radic Biol Med 1995; 19:669-704.
34. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8:344-348. (Pubitemid 16042204)
35. Tschudi M, Mesaros S, Lüscher T, Malinski T, et al. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27:32-35. (Pubitemid 26017677)
36. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens 2006; 24:151-158. (Pubitemid 41818100)
37. Guerrero E, Voces F, Ardanaz N, Montero MJ, Arévalo M, Sevilla MA. Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 42:348-355. (Pubitemid 37071690)
38. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:1234-1241.
39. Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: still in open question. JAMA 2008; 300:2180-2181.
40. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93:9114-9119. (Pubitemid 26282027)
41. Fleming I, Fisslthaler B, Dixit M, Busse R. Role of PECAM-1 in the shear-stress-induced activation of Akt and the endothelial nitric oxide synthase (eNOS) in endothelial cells. J Cell Sci 2005; 118:4103-4111. (Pubitemid 41488949)
42. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49:185-196. (Pubitemid 8032550)
43. Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility. Biochem Pharmacol 1984; 33:2615-2622. (Pubitemid 14098782)
44. Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38:922-929. (Pubitemid 33104703)